The SMA/U7 triple mutant mouse (SMN2+/+;Smn-/-;U7-ESE-B+) harbors the Tg(SMN2)89 transgene and Smn1 null allele described for the severe type I spinal muscular atrophy (SMA) mouse model, as well as the U7-ESE-B transgene designed to correct the human SMN2 splicing defect and result in amelioration of SMA phenotype.
Daniel Schuemperli, Institute of Cell Biology, University of Bern
Genetic Background | Generation |
---|---|
|
Allele Type | Gene Symbol | Gene Name |
---|---|---|
Targeted (Reporter, Null/Knockout) | Smn1 | survival motor neuron 1 |
Allele Type |
---|
Transgenic (Hypomorph, Inserted expressed sequence, Humanized sequence) |
Allele Type |
---|
Transgenic (Reporter, Knockdown) |
Mice homozygous for the Tg(SMN2)89 transgene, homozygous for Smn1 null and harboring the U7-ESE-B transgene (SMN2+/+;Smn-/-;U7-ESE-B+) are the triple mutant mouse model called SMA/U7. They harbor the Tg(SMN2)89 transgene and Smn1 null allele described for the severe type I spinal muscular atrophy (SMA) mouse model, as well as the U7-ESE-B transgene designed to correct the SMA-causitive SMN2 splicing defect and ameliorate SMA phenotype. Details are below.
The Tg(SMN2)89Ahmb transgene expresses the entire human SMN2 gene, whereas no endogenous Smn1 expression is observed from the Smn1 null allele (Smn1tm1Msd). Mice homozygous for Tg(SMN2)89 (SMN2+/+) and homozygous for Smn1 null (Smn-/-) are a severe type I SMA mouse model that, when coisogenic on an FVB/NJ genetic background (JAX Stock No. 005024 ; FVB.SMN2+/+;Smn-/-), exhibits symptoms, neuropathology and early lethality (4-7 days) similar to human type I SMA patients.
As an addition to that SMA model, the SMA/U7 strain also harbors the U7-ESE-B transgene containing the therapeutic U7-ESE-B cassette as well as a hPGK1 promoter-driven EGFP. The U7-ESE-B cassette encodes an antisense oligonucleotide specifically directed to the 3prime region of human SMN2 gene exon 7 (known to have the single nucleotide difference that disrupts an SF2/ASF/SRSF1 binding site-containing exonic splicing enhancer) with a "tail" of additional exonic splicing enhancer motifs to provide trans-acting enhancers.
Mice homozygous for Tg(SMN2)89, homozygous for Smn1 null and harboring the U7-ESE-B transgene (SMN2+/+;Smn-/-;U7-ESE-B+) are called SMA/U7. The U7-ESE-B oligonucleotide has been shown to have nearly complete exon 7 inclusion into SMN1 and ~89% inclusion into SMN2 in cell culture models. The U7-ESE-B transgene copy number is variable (see protocol information below), and SMA/U7 mice with higher U7-ESE-B copy number show greater phenotype rescue. Specifically, SMA/U7 mice with ~one U7-ESE-B transgene copy survive up to 3 weeks. SMA/U7 mice with ~five U7-ESE-B transgene copies exhibit life extension to more than one year, and an almost complete recovery of muscle functions and other disease parameters. The phenotype described above is for SMA/U7 mice on a mixed FVB/N, C57BL/6J, DBA/2J genetic background. The donating investigator reports that this mixed background generally results in a more severe SMA phenotype when compared to mice of the same genotype on an FVB genetic background. EGFP fluorescence is observed in blood samples.
The SMA/U7 mice harbor several mutations/transgenes, as described below.
Creation of the Tg(SMN2)89 transgene (SMN2) and Smn1 null allele (Smn1tm1Msd; also called Smn-) are described for the severe type I SMA mouse model on an FVB/NJ background (JAX Stock No. 005024). The Tg(SMN2)89 transgene insertion site is on chromosome 6. These FVB.SMN2;Smn- mice were maintained on an FVB/NJ background prior to being used as below.
The U7-ESE-B transgenic mice were created by Dr. Daniel Schuemperli (Institute of Cell Biology [IZB], University of Bern, Switzerland) using a lentiviral transgenic approach. The U7-ESE-B splicing correction cassette encodes a tailed antisense oligonucleotide directed to the 3prime part of human SMN2 exon 7 and an additional splicing enhancer sequence. To create this cassette, a 570 bp region of the U7 wildtype gene (Rnu7) was obtained containing 341 bp 5prime flanking sequence (including the distal and proximal sequence promoter elements [DSE and PSE]), 62 bp U7 snRNA coding region and 167 bp 3prime sequence (including the 3prime box). Next, several in vitro modifications were made within the U7 snRNA coding region, as detailed below.
The 5’GGA non-complementary "tail" sequence (GGAGGACGGAGGACGGAGGAC), predicted to mimic the exonic splicing enhancer (ESE) sequence of an SF2/ASF/SRSF1 binding site, was introduced.
The antisense sequence complementary to the histone downstream element in replication-dependent histone pre-mRNAs was changed to a sequence binding to positions 33-50 in the 3prime region (position B [also called B1]) of the weak exon 7 of human SMN2.
The Sm binding site (aatttGtCT) was changed to the Sm OPT sequence (aatttTtGG ; corresponding to the consensus sequence found in spliceosomal snRNAs). As a consequence, the resulting snRNA no longer binds the U7-specific Sm-like proteins Lsm10 and Lsm11, but rather the five standard Sm proteins found in spliceosomal snRNPs. These changes in snRNP assembly render the RNA non-functional for histone RNA processing and additionally allow it to accumulate in cell nuclei ~3 times more efficiently.
The resulting U7-ESE-B splicing correction cassette was introduced into the third generation (self-inactivating) lentiviral vector pRRL-SIN-cPPT-hPGK-GFP-WPRE. The resulting ~4.4 kbp transgene had U7-ESE-B inserted upstream of the hPGK promoter and in sense orientation with EGFP.
Lentiviral transgenesis was performed by perivitelline injection into B6D2G1 (derived from C57BL/6J x DBA/2J mice) fertilized oocytes. Founder female epfl-4 (brown coat color and 27.8 transgene copy number) was bred to a male FVB.SMN2;Smn- (JAX Stock No. 005024) to generate germline carriers. The triple mutant colony was maintained by breeding mice homozygous for the SMN2 transgene, heterozygous for the Smn1 null allele and harboring the U7-ESE-B transgene (SMN2+/+;Smn+/-;U7-ESE-B+) together for more than 15 generations. The colony was bred to FVB.SMN2;Smn- (JAX Stock No. 005024) for ~2-4 generations overall. The donating investigator reports U7-ESE-B transgene copy number is variable, selected breeders with higher copy number and suggests at least some of the transgene copies are linked. In 2016, SMN2+/+;Smn+/-;U7-ESE-B+ mice with ~8 copies of U7-ESE-B (and gray or white coat color) were sent to the Mutant Mouse Regional Resource Center node at The Jackson Laboratory (MMRRC-JAX).
The third generation lentiviral vector pRRL-SIN-cPPT-hPGK-GFP-WPRE is composed of U3 sequences from Rous sarcoma virus (RSV-RU5), HIV-1 packaging signal (Ψ), HIV-1 central polypurine tract (cPPT), human phosphoglycerate kinase promoter, enhanced green fluorescent protein gene (EGFP), woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) and self-inactivating deletions in the U3 region of the 3prime LTR.
Expressed Gene | lacZ, beta-galactosidase, E. coli |
---|---|
Site of Expression | The expression of the lacZ gene in tissues where Smn is normally expressed was noted. |
Expressed Gene | SMN2, survival of motor neuron 2, centromeric, human |
Site of Expression | Grm7Tg(SMN2)89Ahmb |
Expressed Gene | SMN2, survival of motor neuron 2, centromeric, human |
Expressed Gene | GFP, Green Fluorescent Protein, |
Site of Expression | EGFP fluorescence is observed in blood samples. |
Depending upon the experiment, the following may be appropriate control strain(s):
--Mice harboring the Tg(SMN2)89 transgene (SMN2) and Smn1 null targeted mutation (Smn1tm1Msd; also called Smn-) are described for the severe type I SMA mouse model. Such mice are available on an FVB/NJ genetic background (fully congenic N10 [007949] or incipient congenic N5 [Stock No. 005024]), and a C57BL/6J genetic background (Stock No. 006773).
Allele Name | targeted mutation 1, Michael Sendtner |
---|---|
Allele Type | Targeted (Reporter, Null/Knockout) |
Allele Synonym(s) | SMN- |
Gene Symbol and Name | Smn1, survival motor neuron 1 |
Gene Synonym(s) | |
Expressed Gene | lacZ, beta-galactosidase, E. coli |
Site of Expression | The expression of the lacZ gene in tissues where Smn is normally expressed was noted. |
Strain of Origin | 129P2/OlaHsd |
Chromosome | 13 |
Molecular Note | A lacZ-neo cassette was inserted into exon 2 by homologous recombination resulting in an in-frame fusion of lacZ to exon 2. Homozygous mutant embryos were identified up to 80 hours post coitum. The expression of the lacZ gene in tissues where Smn is normally expressed was noted. |
Mutations Made By | Michael Sendtner |
Allele Name | transgene insertion 89, Arthur H M Burghes |
---|---|
Allele Type | Transgenic (Hypomorph, Inserted expressed sequence, Humanized sequence) |
Allele Synonym(s) | SMN2; Tg(SMN2)89Ahmb |
Gene Symbol and Name | Grm7, glutamate receptor, metabotropic 7 |
Gene Synonym(s) | |
Promoter | SMN2, survival of motor neuron 2, centromeric, human |
Expressed Gene | SMN2, survival of motor neuron 2, centromeric, human |
Site of Expression | Grm7Tg(SMN2)89Ahmb |
Strain of Origin | FVB/N |
Chromosome | 6 |
Molecular Note | A 35.5 kb genomic fragment containing the human survival motor neuron 2 (SMN2) gene and promoter was used for the transgene. The transgene is ubiquitously expressed in all tissues examined by Northern blot analysis. Line 89 carries 1 copy of the transgene integrated into intron 4 of the gene. RT-PCR confirmed reduced expression of the gene the transgene is integrated into. |
Mutations Made By | Arthur Burghes, The Ohio State University |
Allele Name | transgene insertion 4, Daniel Schuemperli |
---|---|
Allele Type | Transgenic (Reporter, Knockdown) |
Allele Synonym(s) | U7-ESE-B |
Gene Symbol and Name | Tg(Rnu7-SMN2*,PGK1-EGFP)4Dasch, transgene insertion 4, Daniel Schuemperli |
Gene Synonym(s) | |
Promoter | PGK1, phosphoglycerate kinase 1, human |
Promoter | Rnu7, U7 small nuclear RNA, mouse, laboratory |
Expressed Gene | SMN2, survival of motor neuron 2, centromeric, human |
Expressed Gene | GFP, Green Fluorescent Protein, |
Site of Expression | EGFP fluorescence is observed in blood samples. |
Strain of Origin | C57BL/6J x DBA/2J |
Chromosome | UN |
Molecular Note | The U7-ESE-B splicing correction cassette encodes a tailed antisense oligonucleotide directed to the 3' part of human SMN2 exon 7 and an additional splicing enhancer sequence. To create this cassette, a 570 bp region of the U7 wild-type gene (Rnu7) was obtained containing 341 bp 5' flanking sequence (including the distal and proximal sequence promoter elements [DSE and PSE]), 62 bp U7 snRNA coding region and 167 bp 3' sequence (including the 3' box). The 5'GGA non-complementary "tail" sequence (GGAGGACGGAGGACGGAGGAC), predicted to mimic the exonic splicing enhancer (ESE) sequence of an SF2/ASF/SRSF1 binding site, was introduced. The antisense sequence complementary to the histone downstream element in replication-dependent histone pre-mRNAs was changed to a sequence binding to positions 33-50 in the 3' region (position B [also called B1]) of the weak exon 7 of human SMN2. The Sm binding site (aatttGtCT) was changed to the Sm OPT sequence (aatttTtGG ; corresponding to the consensus sequence found in spliceosomal snRNAs). As a consequence, the resulting snRNA no longer binds the U7-specific Sm-like proteins Lsm10 and Lsm11 but rather the five standard Sm proteins found in spliceosomal snRNPs. These changes in snRNP assembly render the RNA non-functional for histone RNA processing and additionally allow it to accumulate in cell nuclei about 3 times more efficiently. The resulting U7-ESE-B splicing correction cassette was introduced into the third generation (self-inactivating) lentiviral vector pRRL-SIN-cPPT-hPGK-GFP-WPRE. The resulting approximate 4.4 kbp transgene had the U7-ESE-B inserted upstream of the hPGK promoter and in sense orientation with EGFP. Line 4 has 8 copies of the transgene. |
The Tg(SMN2)89 transgene (SMN2) on chromosome 6, the Smn1 null targeted mutation (Smn1tm1Msd or Smn-) on chromosome 13, and the randomly inserted U7-ESE-B transgene are not linked and will segregate independently.
Mice homozygous for Tg(SMN2)89Ahmb, homozygous for Smn1 null and carrying the U7-ESE-B transgene (SMN2+/+;Smn-/-;U7-ESE-B+) are called SMA/U7.
The Mutant Mouse Regional Resource Center node at The Jackson Laboratory (MMRRC-JAX) will maintain the live colony by breeding mice homozygous for Tg(SMN2)89Ahmb, heterozygous for Smn1 null, and carrying U7-ESE-B with mice homozygous for Tg(SMN2)89Ahmb, wildtype at the Smn1 locus and carrying U7-ESE-B.
The donating investigator reports U7-ESE-B transgene copy number is variable (suggests at least some of the transgene copies are linked), and SMA/U7 mice with higher U7-ESE-B copy number show greater phenotype rescue.
When using the SMA/U7 mouse strain in a publication, please cite the originating article(s) and include MMRRC stock #41843 in your Materials and Methods section.
Facility Barrier Level Descriptions
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project. We do not guarantee breeding performance and therefore suggest that investigators order more than one breeding pair to avoid delays in their research.
What information were you hoping to find through your search?
How easy was it to find what you were looking for?
We may wish to follow up with you. Enter your email if you are happy for us to connect and reachout to you with more questions.
Please Enter a Valid Email Address
Thank you for sharing your feedback! We are working on improving the JAX Mice search. Come back soon for exciting changes.